Bill would let assessment panel weigh broader evidence for rare and life‑threatening conditions
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
SB 59‑15 would direct the Health Technology Assessment Program to consider clinical trials, peer‑reviewed literature and evidence types typically impractical for rare or life‑threatening diseases, and add technologies recommended in Medicare or national guidelines to the program's prioritized review list.
Senate Bill 59‑15 would change how the state's Health Technology Assessment Program prioritizes and evaluates medical technologies. Committee staff said the bill adds a category for technologies recommended for Medicare populations or by nationally recognized expert treatment guidelines and requires expanded evidence review for life‑threatening or rare diseases.
Sponsor Senator Harris said the program "hasn't been looked at and been revised" in 20 years and asked for flexibility to consider technologies that could help patients. Public testimony from rare‑disease families and clinicians emphasized that randomized controlled trials are often impractical or unethical in small populations and urged the clinical committee to consider other valid evidence when making coverage recommendations.
Carolina Sommer, a rare‑disease parent, told the committee: "SB 59 15 is important because it recognizes the way we study treatments for common diseases does not always work for rare or life threatening ones." Lisa Woodard, a retired pharmacy professor, described a personal case where an FDA‑approved medical device improved survival but was not covered for public employees and Medicaid in the state.
Proponents said the change would prevent people with rare or life‑threatening conditions from being excluded from coverage solely because their conditions do not fit standard trial models. The committee suspended the hearing to consider the measure further; no final action was taken on Feb. 18.